- Home
- CDTX vs ANNX Comparison
CDTX vs ANNX Comparison
Compare CDTX & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDTX
- ANNX
- Stock Information
- Founded
- CDTX 2012
- ANNX 2011
- Country
- CDTX United States
- ANNX United States
- Employees
- CDTX N/A
- ANNX N/A
- Industry
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- CDTX Health Care
- ANNX Health Care
- Exchange
- CDTX Nasdaq
- ANNX Nasdaq
- Market Cap
- CDTX 333.3M
- ANNX 216.1M
- IPO Year
- CDTX 2015
- ANNX 2020
- Fundamental
- Price
- CDTX $21.68
- ANNX $2.04
- Analyst Decision
- CDTX Strong Buy
- ANNX Strong Buy
- Analyst Count
- CDTX 8
- ANNX 4
- Target Price
- CDTX $41.17
- ANNX $12.50
- AVG Volume (30 Days)
- CDTX 157.5K
- ANNX 1.4M
- Earning Date
- CDTX 05-08-2025
- ANNX 05-12-2025
- Dividend Yield
- CDTX N/A
- ANNX N/A
- EPS Growth
- CDTX N/A
- ANNX N/A
- EPS
- CDTX N/A
- ANNX N/A
- Revenue
- CDTX $302,000.00
- ANNX N/A
- Revenue This Year
- CDTX N/A
- ANNX N/A
- Revenue Next Year
- CDTX N/A
- ANNX N/A
- P/E Ratio
- CDTX N/A
- ANNX N/A
- Revenue Growth
- CDTX N/A
- ANNX N/A
- 52 Week Low
- CDTX $10.14
- ANNX $1.29
- 52 Week High
- CDTX $28.42
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- CDTX 47.21
- ANNX 53.89
- Support Level
- CDTX $18.91
- ANNX $1.92
- Resistance Level
- CDTX $24.91
- ANNX $2.21
- Average True Range (ATR)
- CDTX 1.86
- ANNX 0.17
- MACD
- CDTX -0.18
- ANNX 0.03
- Stochastic Oscillator
- CDTX 33.41
- ANNX 63.79
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.